Get the Stockscreener App
2.98
5.10%
-0.16
After Hours:
3.05
0.07
+2.35%
Galectin Therapeutics Inc stock is traded at $2.98, with a volume of 530.46K.
It is down -5.10% in the last 24 hours and down -5.40% over the past month.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
See More
Previous Close:
$3.14
Open:
$3.11
24h Volume:
530.46K
Relative Volume:
1.13
Market Cap:
$192.13M
Revenue:
-
Net Income/Loss:
$-45.08M
P/E Ratio:
-4.0822
EPS:
-0.73
Net Cash Flow:
$-33.68M
1W Performance:
+0.34%
1M Performance:
-5.40%
6M Performance:
-25.13%
1Y Performance:
+101.35%
1-Day Range:
$2.93
$3.165
1-Week Range:
$2.91
$3.32
52-Week Range:
$1.12
$7.13
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics Inc
Sector
Industry
Phone
678-620-3186
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
2.98 | 202.44M | 0 | -45.08M | -33.68M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
496.83 | 121.97B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.67 | 81.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
766.92 | 47.74B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.92 | 43.93B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
316.99 | 35.67B | 4.98B | 69.60M | 525.67M | 0.5198 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Resumed | H.C. Wainwright | Buy |
| Aug-13-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-19 | Initiated | B. Riley FBR | Buy |
| Dec-07-17 | Reiterated | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-19-17 | Initiated | ROTH Capital | Buy |
| Mar-30-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-03-16 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| Sep-29-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-28-16 | Downgrade | ROTH Capital | Buy → Sell |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Sep-21-15 | Initiated | H.C. Wainwright | Buy |
| Aug-01-14 | Downgrade | Aegis Capital | Buy → Hold |
| Jul-30-14 | Reiterated | MLV & Co | Buy |
| Jul-29-14 | Reiterated | MLV & Co | Buy |
| Apr-02-14 | Reiterated | MLV & Co | Buy |
| Feb-10-14 | Reiterated | Aegis Capital | Buy |
| Jan-09-14 | Reiterated | Aegis Capital | Buy |
| Dec-03-13 | Initiated | MLV & Co | Buy |
| Aug-19-13 | Reiterated | Aegis Capital | Buy |
View All
Galectin Therapeutics Inc Stock (GALT) Latest News
Galectin Therapeutics Adjusts Key NASH Cirrhosis Trial, Resetting Expectations for GALT - TipRanks
Is Galectin Therapeutics Inc. in a bullish channel2025 Short Interest & Weekly Breakout Watchlists - mfd.ru
Trend Review: Is Galectin Therapeutics Inc in a bullish channelJuly 2025 Decliners & AI Forecast Swing Trade Picks - baoquankhu1.vn
Does Galectin Therapeutics Inc. have a sustainable dividendWeekly Stock Recap & Daily Momentum Trading Reports - mfd.ru
Is Galectin Therapeutics Inc stock a buy or sell2025 Earnings Surprises & Low Risk High Win Rate Picks - baoquankhu1.vn
What is the long term forecast for Galectin Therapeutics Inc. stock2025 Year in Review & Real-Time Buy Signal Notifications - mfd.ru
Will Galectin Therapeutics Inc. stock deliver long term returns2025 Volatility Report & Safe Capital Allocation Plans - mfd.ru
What’s the outlook for Galectin Therapeutics Inc.’s sectorMarket Growth Review & Fast Exit/Entry Strategy Plans - mfd.ru
Buy Signal: Whats the outlook for Galectin Therapeutics Incs sectorPortfolio Return Report & AI Based Trade Execution Alerts - baoquankhu1.vn
Short Covering: How is MLKN managing supply chain issues2025 Trading Recap & Fast Moving Stock Watchlists - baoquankhu1.vn
Aug Chart Watch: Is Galectin Therapeutics Inc gaining market shareJuly 2025 Recap & Accurate Intraday Trade Tips - baoquankhu1.vn
Galectin Therapeutics Inc.'s (NASDAQ:GALT) market cap dropped US$39m last week; Individual investors bore the brunt - simplywall.st
Can Galectin Therapeutics Inc expand into new marketsJobs Report & Real-Time Volume Analysis - baoquankhu1.vn
Meme Stocks: Will Galectin Therapeutics Inc outperform its industry peersMarket Activity Report & Expert Approved Momentum Ideas - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc.GALT - yourwyominglink.com
Galectin Therapeutics Inc.'s (NASDAQ:GALT) top owners are retail investors with 55% stake, while 20% is held by insiders - Yahoo Finance
Moving Averages: What is the Moat Score of WVVIPBuy Signal & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Analysis Recap: Can Galectin Therapeutics Inc be the next market leaderTrade Entry Report & Smart Investment Allocation Insights - baoquankhu1.vn
Portfolio Update: Is DNAWS a potential multi baggerEarnings Beat & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Galectin Therapeutics Inc. (NASDAQ:GALT) Short Interest Update - MarketBeat
Galectin Therapeutics Under Investigation, Stock Plummets 28.9% - Intellectia AI
Is Galectin Therapeutics Inc. gaining market shareJuly 2025 Analyst Calls & Safe Entry Point Identification - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Galectin Therapeutics Inc. (GALT) And Encourages Shareholders to Reach Out - ACCESS Newswire
Insider Buy: Can BROG navigate macro headwindsWeekly Investment Summary & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Growth Review: Is Galectin Therapeutics Inc stock affected by interest rate hikesQuarterly Earnings Report & Daily Growth Stock Investment Tips - Bộ Nội Vụ
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Galectin Therapeutics Inc. (GALT) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Galectin Therapeutics Inc. (GALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - accessnewswire.com
Galectin Therapeutics director Marc Rubin resigns from board By Investing.com - Investing.com India
Galectin Therapeutics announces board resignation of Marc Rubin - TipRanks
Galectin Therapeutics director Marc Rubin resigns from board - Investing.com
Bronstein, Gewirtz & Grossman, LLC Encourages Galectin Therapeutics Inc. (GALT) Shareholders to Inquire about Securities Investigation - accessnewswire.com
Will Galectin Therapeutics Inc. stock continue dividend increasesJuly 2025 Closing Moves & Detailed Earnings Play Strategies - ulpravda.ru
Bronstein, Gewirtz & Grossman, LLC Is Investigating Galectin Therapeutics Inc. (GALT) And Encourages Investors to Connect - ACCESS Newswire
Galectin Therapeutics Inc.'s (NASDAQ:GALT) Last Week's 23% Decline Must Have Disappointed Individual Investors Who Have a Significant Stake - 富途牛牛
Can Galectin Therapeutics Inc. (PHPN) stock sustain institutional flowsJuly 2025 Drop Watch & AI Enhanced Execution Alerts - Улправда
Is Galectin Therapeutics Inc. (PHPN) stock a safe buy pre earningsJuly 2025 Spike Watch & Fast Gain Swing Trade Alerts - Улправда
Will Galectin Therapeutics Inc. stock benefit from automationJuly 2025 Trade Ideas & High Accuracy Investment Entry Signals - Улправда
Fraud Investigation Opened: Levi & Korsinsky Investigates Galectin Therapeutics Inc. (GALT) on Behalf of Shareholders - ACCESS Newswire
Is Galectin Therapeutics Inc. stock resilient to inflationJuly 2025 Review & Precise Swing Trade Entry Alerts - Улправда
How buybacks impact Galectin Therapeutics Inc. stock value2025 Momentum Check & Consistent Return Strategy Ideas - Улправда
MACD Signal: Will Galectin Therapeutics Inc. stock benefit from automation2025 Technical Overview & Community Consensus Trade Alerts - Улправда
Is Galectin Therapeutics Inc. stock attractive for income investors2025 Growth vs Value & High Win Rate Trade Tips - Улправда
Institution Moves: Will Galectin Therapeutics Inc. (PHPN) stock beat Nasdaq index returnsJuly 2025 Earnings & Safe Investment Capital Preservation Plans - ulpravda.ru
Market Trends: Will Galectin Therapeutics Inc PHPN stock beat Nasdaq index returnsJuly 2025 Retail & Real-Time Volume Analysis Alerts - Bộ Nội Vụ
Fraud Investigation: Levi & Korsinsky Investigates Galectin Therapeutics Inc. (GALT) on Behalf of Shareholders - ACCESS Newswire
GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
Galectin Therapeutics CFO sells $233k in shares By Investing.com - Investing.com Nigeria
Galectin Therapeutics CFO sells $233k in shares - Investing.com
Insider Sell: Jack Callicutt Sells 60,000 Shares of Galectin The - GuruFocus
Khurram Jamil Sells 21,446 Shares of Galectin Therapeutics (NASDAQ:GALT) Stock - MarketBeat
Galectin Therapeutics (NASDAQ:GALT) CFO Sells $58,438.80 in Stock - MarketBeat
Galectin Therapeutics Inc Stock (GALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Galectin Therapeutics Inc Stock (GALT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| LEWIS JOEL | President and CEO |
Jan 02 '26 |
Option Exercise |
0.00 |
84,000 |
0 |
916,592 |
| LEWIS JOEL | President and CEO |
Jan 06 '26 |
Sale |
3.58 |
37,698 |
134,853 |
832,592 |
| LEWIS JOEL | President and CEO |
Jan 05 '26 |
Sale |
3.91 |
27,731 |
108,342 |
870,290 |
| LEWIS JOEL | President and CEO |
Jan 02 '26 |
Sale |
4.20 |
18,571 |
77,939 |
898,021 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 02 '26 |
Option Exercise |
0.00 |
60,000 |
0 |
67,614 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 05 '26 |
Sale |
3.90 |
25,732 |
100,298 |
27,968 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 06 '26 |
Sale |
3.67 |
20,354 |
74,695 |
7,614 |
| CALLICUTT JACK W | Chief Financial Officer |
Jan 02 '26 |
Sale |
4.20 |
13,914 |
58,394 |
53,700 |
| Jamil Khurram | Chief Medical Officer |
Jan 02 '26 |
Option Exercise |
0.00 |
60,000 |
0 |
60,000 |
| Jamil Khurram | Chief Medical Officer |
Jan 05 '26 |
Sale |
3.90 |
25,499 |
99,408 |
21,446 |
1.18%
0.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):